This study explores adding new drugs, duvelisib or CC-486, to standard treatment for peripheral T-cell lymphoma. Peripheral T-cell lymphoma is a type of cancer affecting certain blood cells. Duvelisib is designed to stop cancer cell growth by blocking enzymes, while CC-486 and other chemotherapy drugs work to kill or stop the cancer cells from spreading. The trial checks if this new approach is better than the usual treatment.

Participants are divided into three groups, each receiving different treatment combinations. Treatment cycles last 21 days, repeating up to 6 times unless the disease worsens or side effects are too severe. After treatment, follow-up visits occur for up to 5 years to monitor progress.

• Study lasts up to 5 years with regular follow-ups.
• Patients receive treatment every 21 days, up to 6 cycles.
• Potential risks include common chemotherapy side effects.

To participate, patients must have a specific type of lymphoma and meet other health criteria, like no other recent cancer treatments. Women of childbearing age must test negative for pregnancy. The study excludes those with other active infections or certain heart conditions.